Gilead Sciences has secured three U.S. Food and Drug Administration (FDA) approvals in less than four months. The most recent, on August 27, was for Bixlenvo as a daily oral medication for the treatment of virologically suppressed adults with HIV infection. Prior to this, Trodelvy received two new approvals on June 24 for the treatment of triple-negative breast cancer, and Hepcludex received accelerated approval on May 22 for the treatment of chronic hepatitis delta virus (HDV) infection.
The company's stock price has risen by over 21% year-to-date. Additionally, Gilead Sciences reported second-quarter revenue of $7.6 billion, an 8% increase year-over-year, and projects full-year revenue to be between $30.1 billion and $30.4 billion.
Faster global financial news!
Gilead Sciences (GILD) received its third FDA approval in less than four months, with the latest being Bixlenvo approved on August 27 for the treatment of HIV-infected individuals.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
Previous: Binance founder CZ attended a meeting of Kyrgyzstan's National Crypto Council, stating that the country has made "real progress" in crypto regulation, local banking channels, and stablecoins.
|
Next: Israeli destruction campaign expands to West Bank's 'food basket,' razing Palestinian farmland and olive groves
24H Trending
-
1
Oracle, Meta, and SpaceX credit default swaps (CDS) hit all-time highs, as the market anticipates a surge in AI-related bond issuance in Q4.
-
2
Liu Jun, President of Industrial and Commercial Bank of China (ICBC): Commercial Banks Bear Heavier Financial and Legal Responsibilities Than Central Banks in AI Deployment
-
3
Bain Survey: Chinese Consumers Prioritize Technology in Car Purchases, While Europeans and Americans Still Value Price; Western Automakers Face Dual Pressure
-
4
Anthropic pitches AI safety bill that would require judge's permission to block models
-
5
NextDC's data center project in Australia faces power supply delays due to resident protests, leading to a more than one-third reduction in its FY2027 earnings guidance and a 45% plunge in its stock price.
-
6
Media reports: Amazon Web Services (AWS) has billions of dollars worth of NVIDIA chips backlogged in its warehouses due to power shortages, leading to negative free cash flow.
-
7
Hansoh Pharmaceutical inks up to $15B drug deal with Roche, China's innovative drug out-licensing hits $130B
-
8
U.S. equity index futures rose, boosted by strong earnings reports from AI-related companies.
-
9
King Charles III of the UK praised Oman's peaceful efforts in reopening the Strait of Hormuz.
-
10
Oracle founder Larry Ellison pledged shares in Tesla, SpaceX, and other companies to secure bank loans to fund his son's bid for Warner Bros.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
